Filament Health Corp. FLHLF announced that the U. S. Patent and Trademark Office (USPTO) issued a patent that will allow the company to extract and standardize natural psilocybin and associated psychedelic compounds.
Benjamin Lightburn, CEO of the company, commented: “The issuance of Filament's first US patent is a testament to the strength of our drug development platform.”
The company also holds the first-ever Canadian patent for extracting and standardizing natural psilocybin for a public company, as announced in August 2021. The process is undertaken by Filament’s subsidiary, Psilo Scientific.
”Shepherding an application to issuance is different in every country, therefore having our IP validated by more than one government is evidence of our team's talent for innovation by truly diverse criteria,” added Taran Grey, director of intellectual property.
Photo: Courtesy of Marco Allegretti on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!